This pilot research study will evaluate the effect of giving dogs with Protein Losing Nephropathy (PLN) the supplement silymarin in combination with established standard medications. Dogs will receive silymarin for three months. During this time, dogs will have their kidney values, blood pressure, and urine protein closely monitored.
Silymarin is a supplement that is derived from the milk thistle plant. It has potent antioxidant properties and has been used to treat liver disease in dogs for years. Research has shown silymarin to be effective in preventing or reducing liver inflammation secondary to toxins and various medications. Although silymarin is commonly used as a therapy for canine liver disease, it has not been evaluated for beneficial effects in kidney disorders.
- Dogs with stable proteinuria (UPC >2.0, stable over previous 3 months)
- Dogs are receiving standard therapy (protein-restricted diet, ACE-inhibitor therapy, omega fatty acid supplementation)
- IRIS Stage 4 chronic kidney disease (serum creatinine >5.0)
- Progressive azotemia (> 2mg/dL in creatinine over past 3 months)
- NSAID therapy
- Uncontrolled hypertension
- Dogs will received silymarin orally, three times daily for three months
- Free evaluation by board certified internal medicine specialists
- Free blood work, blood pressure, and urine testing during study period
- Silymarin supplement is provided FREE
For more information or to have your dog enrolled in the study, please contact:
Dr. JD Foster